NCT00982202 - Pioglitazone in Alzheimer Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2002

Primary Completion Date

January 31, 2005

Study Completion Date

January 31, 2005

Conditions

Alzheimer Disease

Interventions

DRUG

pioglitazone

15mg tablet daily, increase by one pill at one-week intervals based on reported tolerability; maintain best tolerated dose (1 to 3 tablets daily) for \~18months

DRUG

Placebo

1 to 3 tablets daily for \~18 months

Trial Locations (2)

22908

University of Virginia, Charlottesville

44120

University Hospitals of Cleveland, Cleveland

All Listed Sponsors

collaborator

Takeda Pharmaceuticals North America, Inc.

INDUSTRY

lead

National Institute on Aging (NIA)

NIH